GWM
ROIV icon

Geneos Wealth Management’s Roivant Sciences ROIV Stock Holding History

Geneos Wealth Management’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.54K Hold
100
– – ﹤0.01% 2247
2026
Q1 		$2.77K Hold
100
– – ﹤0.01% 2265
2025
Q4 		$2.17K Hold
100
– – ﹤0.01% 2303
2025
Q3 		$1.51K Sell
100
-42
-30% -$520 ﹤0.01% 2360
2025
Q2 		$1.6K Hold
142
– – ﹤0.01% 2869
2025
Q1 		$1.43K Buy
142
+42
+42% +$454 ﹤0.01% 2849
2024
Q4 		$1.18K Hold
100
– – ﹤0.01% 2735
2024
Q3 		$1.15K Hold
100
– – ﹤0.01% 2419
2024
Q2 		$1.06K Hold
100
– – ﹤0.01% 1973
2024
Q1 		$1.05K Buy
+100
New +$1.08K ﹤0.01% 2009

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Geneos Wealth Management's ROIV Position: Q2 2026 in Review

Geneos Wealth Management held its Roivant Sciences (ROIV) position steady in Q2 2026 at 100 shares worth $3.54K. The position accounts for ﹤0.01% of the portfolio, ranked #2247.

Geneos Wealth Management first reported a position in ROIV in Q1 2024 and has held it in 10 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Geneos Wealth Management held 100 shares of Roivant Sciences worth $3.54K as of Q2 2026.
  • Geneos Wealth Management left its Roivant Sciences share count unchanged in Q2 2026.
  • Roivant Sciences made up ﹤0.01% of Geneos Wealth Management's portfolio in Q2 2026, its #2247 holding.
  • Geneos Wealth Management first reported a position in Roivant Sciences in Q1 2024 and has held it in 10 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.